Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 1 of 3 for:    Cervical Cancer | Nigeria
Previous Study | Return to List | Next Study

Human Papillomavirus Epidemiology in Nigeria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT00804466
Recruitment Status : Recruiting
First Posted : December 8, 2008
Last Update Posted : November 8, 2019
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Tracking Information
First Submitted Date  ICMJE December 5, 2008
First Posted Date  ICMJE December 8, 2008
Last Update Posted Date November 8, 2019
Actual Study Start Date  ICMJE July 6, 2009
Estimated Primary Completion Date December 30, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 19, 2018)
Sensitivity of triage methods [ Time Frame: cross-sectional ]
Cervical Histopathology
Original Primary Outcome Measures  ICMJE Not Provided
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Human Papillomavirus Epidemiology in Nigeria
Official Title  ICMJE Epidemiologic and Molecular Features of Cervical Cancer in Nigeria - Project Itoju (Care)
Brief Summary


  • Cervical cancer is caused by persistent infection of the lining of the cervix with some kinds of human papillomaviruses (HPV). These HPV infections are distantly related to the viruses that cause warts on the skin. Like common wart viruses, most women who have cervical infections with HPV resolve the infections within 2 years without any need for treatment. Cervical infections that do not go away may cause disease that can turn into cancer after many years.
  • Only one study has been done in Nigeria to learn how many women have HPV infection. The results of the study differed from most other studies in the world because older women were much more likely to be infected. This study with learn whether the results found in the previous study are true in Irun also, the site of the current study.


  • To examine the age distribution of HPV infection and relationship to cancer of the cervix among Nigerian women.
  • To understand how different screening methods, including HPV testing, could best reduce the risk of cervical cancer in Nigerian women.


- Women residing in Irun, Nigeria, who are 15 years of age or older.


  • Participants complete a brief questionnaire related to demographics, household and living conditions and a longer survey with questions related to reproductive history, family history, illnesses, stressful life events and sexual history (U. of Michigan collaboration).
  • Participants have a cervical examination, HPV test, Pap test and blood test.
  • Women whose tests show they are infected with HPV or have cervical disease will do the following:
  • see a doctor and have cervical biopsies of all white abnormal areas (removal of a small tissue sample from the cervix)
  • have photographs of the cervix taken
  • have a cervical scraping for a new kind of HPV test.
  • Some women with normal test results are also asked to see a doctor to check the validity of the testing
  • Women with cervical disease receive treatment by a specialist and remain in the program until treatment is successfully completed or a final diagnosis is reached.
  • Participants may be contacted for followup up to 5 years after the final diagnosis is made.
Detailed Description

BACKGROUND: Cervical cancer, caused by persistent infection with approximately 15-20 genotypes of carcinogenic human papillomavirus (HPV) infection, is the second leading cause of female cancer. Cytology (Pap smears) and the new HPV vaccines are not widely available in poor regions. Immediate treatment of HPV-infected older women by cryotherapy might have greater impact.

Although the same HPV types cause cervical cancer everywhere, and the same stages (infection, persistence vs. clearance, progression to precancer, and invasion) typify cervical carcinogenesis, the patterns of age-specific prevalence of HPV vary widely. These patterns are important for secondary prevention strategies relying on HPV DNA testing.

In many regions, including the US, HPV infections appear as classical sexually-transmitted agents, with peak cervical DNA prevalence at young ages (approximately 20) and low prevalence at older ages. However, in Nigeria, HPV prevalence is high (greater than or equal to 15%) at all ages according to the one study performed in urban Ibadan by Franceschi s group at IARC (n=932 women). This pattern is very uncommon. High prevalence at all ages would preclude use of HPV testing in low-cost strategies, due to poor positive predictive value. One possibly relevant element is the marital structure in Nigeria; a man often has multiple wives.

OBJECTIVES: The major objectives are: 1) To estimate age-specific HPV prevalences in Irun, Nigeria; 2) To investigate epidemiologic risk factors for HPV and cervical intraepithelial neoplasia in this population; 3) To examine the performance of screening options; 4) To assess the correlation of HPV among co-wives, comparing households with multiple wives with those with single wives; and 5) To validate the performance of rapid HPV, an inexpensive HPV test designed for public-sector use in settings like Irun.

ELIGIBILITY: All non-pregnant women aged 15+, without hysterectomy, will be eligible if they can provide written informed consent. Unmarried women less than 21 will be enrolled only with parental consent. Sexually active women will be examined and asked for cervical specimens; self-reported virginal women will be asked for a 10-ml blood sample only.

DESIGN: This is a cross-sectional screening study of 1500 women in Irun, a Nigerian village. Unlike the IARC study, we will incorporate cytology, visual inspection, and colposcopic biopsy of women that test positive by any of the three screening tests. We will determine whether HPV infection at various ages is related to risk of cervical abnormalities. The analyses will include descriptive trend data, multivariable modeling of HPV determinants, and clinical epidemiologic analysis of relative screening test performance in detecting cervical neoplasia.

Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Condition  ICMJE
  • Human Papillomavirus 18
  • Cervical Intraepithelial Neoplasia
  • Human Papillomavirus 16
  • Uterine Cervical Neoplasms
Intervention  ICMJE
  • Device: OncoE6
    HPV oncoprotein assay
  • Device: EVA System
    low-cost colposcope
Study Arms  ICMJE Experimental: Women referred to colposcopy clinic
Triage tests for diagnosis of cervical pre-cancer amongHPV positive women
  • Device: OncoE6
  • Device: EVA System
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: November 5, 2019)
Original Enrollment  ICMJE
 (submitted: December 5, 2008)
Estimated Study Completion Date  ICMJE December 30, 2022
Estimated Primary Completion Date December 30, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE
  • Females who are 15 years to 99 years of age


  • Previous hysterectomy
  • Current pregnancy
  • Inability to give informed consent
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 30 Years to 49 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Julia C Gage, Ph.D. (240) 276-7264
Contact: Mark H Schiffman, M.D. (240) 276-7259
Listed Location Countries  ICMJE Nigeria
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00804466
Other Study ID Numbers  ICMJE 999909045
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
Study Sponsor  ICMJE National Cancer Institute (NCI)
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Mark H Schiffman, M.D. National Cancer Institute (NCI)
PRS Account National Institutes of Health Clinical Center (CC)
Verification Date November 4, 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP